1. Increased frequency of interleukin‐4 and reduced frequency of interferon‐γ and IL‐17‐producing CD4+ and CD8+ cells in scleromyxedema.
- Author
-
Kalli, F., Cioni, M., Parodi, A., Altosole, T., Ferrera, F., Barra, G., De Palma, R., Fenoglio, D., Filaci, G., and Rongioletti, F.
- Subjects
- *
INTERLEUKIN-4 , *T cells , *LYMPHOCYTE subsets , *IMMUNOLOGIC diseases , *CELLS - Abstract
Background: Little is known about the pathogenesis of scleromyxedema, a life‐threatening fibromucinosis disease with immunological dysregulation. Objectives: To investigate on T‐cell phenotype, function and cytokine biology in search of new insights supporting the immunopathogenesis of the disease. Methods: We analysed the frequency of circulating lymphocyte subsets, the T‐cell maturation stage, the generation of antigen‐specific T‐cell lines and T‐cell cytokine secretion. Results: The analysis of T‐cell maturation stage and the TCR spectratyping findings revealed that scleromyxedema patients showed clear immunological signs of long‐lasting immune system activation and stimulation leading to a skewed T‐cell repertoire. Moreover, these analyses showed that both CD4+ and CD8+ T cells from scleromyxedema patients have a profound deficiency (even after stimulation) relatively to the production of IFN‐γ and IL17 with respect to healthy donor control cells, while they are massively skewed towards IL4 secretion after stimulation. Conclusions: Our data indicate that a chronic Th2‐skewed T‐cell response against an unknown target antigen leading to abnormally high IL4 secretion, a pro‐fibrotic cytokine, is a main immunological hallmark of scleromyxedema patients. These results, never reported before, may have a translational therapeutic value due to the availability of anti‐IL4 agents such as dupilumab. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF